InvestorsHub Logo
Followers 4
Posts 269
Boards Moderated 0
Alias Born 03/28/2018

Re: None

Wednesday, 04/04/2018 4:17:11 PM

Wednesday, April 04, 2018 4:17:11 PM

Post# of 7901
TransEnterix does not have a viable platform. Period. SOFAR was happy to dump ALF-X on TRXC because they knew after thousands of hours and hundreds of patients it was just not a viable platform. The clinical data sponsored by SOFAR and TRXC all display excessive surgical times, more post operative pain and a 6% conversion rate.

This platform has been available with a CE mark in Europe since 2013 and has yet to experience just one Commercial sale.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y